Navigation Links
Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
Date:9/30/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 30 /PRNewswire/ -- A global pharmaceutical company has initiated a prospective trial to evaluate the impact of insulin guidelines developed by the Indian National Consensus group in collaboration with Max Neeman, a leading India-based Contract Research Organization. The goal is to provide simple management to the Type II Diabetes patient dependent on insulin.  The study will bring out a comparison between the routine clinical practice and the therapy decided as per the Insulin guidelines.

This large Phase IV study encompasses the northern, southern, western and eastern parts of India with over 1,200 sites and aims to enroll over 25,000 Type II Diabetics. Max Neeman is responsible for site management of all locations across the country and for achieving the enrollment target. To date, the team has successfully enrolled over 12,000 patients in 2 months time and will achieve the target before the stipulated time.

Max Neeman is experienced in endocrinology/metabolic studies having been awarded numerous diabetic trials to date with 98% patient retention rate and target enrollment met by the deadline.

About Max Neeman International

Max Neeman International is one of the leading CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 31 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
2. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
3. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
4. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
5. International Robotic Urology Symposium 2011
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Mindray Medical to Exhibit New Products at 64th China International Medical Equipment Fair
8. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
9. Webmedx and NLP International Team to Bring Natural Language Processing Software to Medical Transcription
10. MedWOW International Medical Equipment Platform Adds Seller Ministores
11. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... December 5, 2016 PharmaBoardroom today releases its new ... ... This report offers companies, investors, policymakers, and stakeholders crucial insight into ... Europe , home to some of the world,s most important ... in Novartis and Roche, and with a number one ranking globally in ...
(Date:12/4/2016)... CAMBRIDGE, Mass. , Dec. 4, 2016 /PRNewswire/ ... a leader in discovering and developing targeted kinase ... announced data from its ongoing Phase 1 trial ... of patients with advanced systemic mastocytosis (SM). Blueprint ... selective inhibitor of D816V mutant KIT. Approximately 90 ...
(Date:12/4/2016)... Dec. 3, 2016 Sickle cell disease (SCD) ... red blood cells that get stuck in veins and ... organ failure, and complications leading to death. Each year, ... SCD, and most of them lack access to comprehensive ... established long-term therapy for SCD, a pill called hydroxyurea ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi ... patients who do not do their research and undergo cosmetic dermatology treatments from unqualified ... midst of a renaissance and every other month a new treatment or device is ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted its first Swirl: A Wine Tasting Event in New York City, with ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... ... undergoing major cosmetic surgery can now take advantage of a cosmetic procedure known ... skin rejuvenation treatment that reduces the appearance of age spots, fine lines, ...
Breaking Medicine News(10 mins):